Alopecia Areata study: Deuruxolitinib
Official title Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
ClinicalTrials.gov ID: NCT07617597
What this study is testing
What is Deuruxolitinib?
This is an investigational oral tablet being studied as a potential treatment for severe alopecia areata. It is designed to block specific immune signals in the body that may be causing hair loss.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see if deuruxolitinib helps regrow hair and is safe for people with severe alopecia areata.
- Who it's for
- Japanese adults aged 18 to 65 with 50% or more scalp hair loss.
- What's involved
- Participants will receive the drug and have regular visits and tests to monitor hair growth and safety.
- Time commitment
- The study lasts several months with scheduled clinic visits during the treatment period.
- Phase 3: a large, late-stage study
- Time commitment: about 24 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Written informed consent has been obtained.
- Japanese people with severe alopecia areata who are between 18 and 65 years of age, inclusive, at the time of informed consent.
- Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months.
- SALT score of 50 or more at both Screening and Baseline.
You likely can't join if
- Treatment with systemic immunosuppressive medications or agents, including Janus kinase inhibitors, within 4 months prior to randomization.
- Treatment with biologics within 6 months prior to Screening.
- Positive test results for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus at Screening.
- History of active tuberculosis, a positive interferon gamma release assay at Screening, or evidence of tuberculosis-related lesions on chest...
- Clinically significant hematologic abnormalities, hepatic impairment, or renal impairment at Screening.
The study team makes the final eligibility decision.
Where it is enrolling
- Asahikawa, Japan
- Bunkyō City, Japan
- Ebina, Japan
- Hamamatsu, Japan
- Ishikawa, Japan
- Kitakyushu, Japan
- Kōtoku, Japan
- Kurashiki, Japan
- Kurume, Japan
- Kyoto, Japan
- Mitaka-shi, Japan
- Niigata, Japan
- Osaka, Japan
- Sapporo, Japan
- Shinjuku-Ku, Japan
- Ube, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 24 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Asahikawa, Japan; Bunkyō City, Japan; Ebina, Japan; Hamamatsu, Japan; Ishikawa, Japan; Kitakyushu, Japan and 10 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.